Gabriela Sabate

AI-first Infrastructure for Healthcare & Biotech | Digital Health | Techstars EIR

📍 United States🔄 Updated September 2026💼 3 investments📅 9 years investing🗓 Last invested Sep 2021
VC🌍 United States
3
Total investments
0
Early stage
1
Mid stage
0
Late stage
9y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Advisor & Investor
Sep 2021
Enabling users to establish #ownership & #control over their Biosamples & derived datasets as Non-fungible Tokens. We call them #BioNFTs 🧬.
Co-Founder, Investor & VP of Strategy & Innovation
May 2017
Biotechnology and Cellular Medicine for Better Health
Experience · 8 entries
All (8)
Investments (2)
Founder (4)
2024
Entrepreneur in Residence
Aug 2024
Were facilitating the growth of Fort Worth’s physical health industry by being the power, resources, and capital behind the citys most valuable commodity: its entrepreneurs. Let’s grow together⤵️
2022
Co-Founder & CEO
Jul 2022
Quralo™ es una plataforma de acceso libre y gratuito para todos los profesionales de la salud enfocada en facilitar las tareas durante la atención a sus pacientes.
2021
Advisor & Investor
Sep 2021
Enabling users to establish #ownership & #control over their Biosamples & derived datasets as Non-fungible Tokens. We call them #BioNFTs 🧬.
2020
Co-Investigator of NIH Grant - COVID-19 Progression Prediction through AI, Metagenomics and EHR
Mar 2020
The National Institute of Biomedical Imaging and Bioengineering is one of 27 Institutes and Centers that comprise the National Institutes of Health (NIH). NIBIB synthesizes the best ideas from the diverse fields of science and engineering to improve human health. Visit us at http://www.nibib.nih.gov This is the official LinkedIn account of NIBIB. Our comment policy, privacy policy, and related notices are posted at http://www.nibib.nih.gov/policies Engagement ≠ endorsement For general information about NIBIB, send us an email at info@nibib.nih.gov
Co-Founder / Advisor
Jan 2020
Lifetime Omics stands at the forefront of global AI-based research in the life sciences, currently developing a pioneering technology that will provide unparalleled access to a vast network of health and omics data for researchers worldwide. Our FAIRLYZ technology will promote and facilitate collaborations with esteemed scientists across research institutions to spearhead the era of AI-based clinical decision support systems (CDSS) that provide diagnosis support, treatment planning, risk assessment, and disease prevention.
Show all 8 entries ↓
Investment activity
2017–2021 · 3 investments
201712020120211
Recent (last 2 years)Earlier